PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of scirepAboutEditorial BoardFor AuthorsScientific Reports
 
Sci Rep. 2017; 7: 17587.
Published online 2017 December 14. doi:  10.1038/s41598-017-17816-x
PMCID: PMC5730568

Hybrid splicing minigene and antisense oligonucleotides as efficient tools to determine functional protein/RNA interactions

Abstract

Alternative splicing is a complex process that provides a high diversity of proteins from a limited number of protein-coding genes. It is governed by multiple regulatory factors, including RNA-binding proteins (RBPs), that bind to specific RNA sequences embedded in a specific structure. The ability to predict RNA-binding regions recognized by RBPs using whole-transcriptome approaches can deliver a multitude of data, including false-positive hits. Therefore, validation of the global results is indispensable. Here, we report the development of an efficient and rapid approach based on a modular hybrid minigene combined with antisense oligonucleotides to enable verification of functional RBP-binding sites within intronic and exonic sequences of regulated pre-mRNA. This approach also provides valuable information regarding the regulatory properties of pre-mRNA, including the RNA secondary structure context. We also show that the developed approach can be used to effectively identify or better characterize the inhibitory properties of potential therapeutic agents for myotonic dystrophy, which is caused by sequestration of specific RBPs, known as muscleblind-like proteins, by mutated RNA with expanded CUG repeats.

Introduction

Alternative splicing (AS) is a co-transcriptional process that leads to a significant increase in proteome diversity13. AS leads to the formation of different mRNA variants from the same precursor transcript due to conditional inclusion or exclusion of alternative exons or their parts depending on the tissue type, developmental stage or disease conditions4. The process is controlled by a group of tissue-specific trans-elements that act as alternative splicing regulators, including muscleblind-like proteins (MBNLs), CUG triplet repeat binding, elav-like family proteins (CELFs) and RNA-binding fox homolog proteins (RBFOXs). They define the splicing pattern of regulated alternative exons by binding to specific RNA sequence/structure motifs (cis-elements)57. The inclusion or exclusion of alternative exons is primarily determined by the interplay of several alternative splicing regulators and other types of regulatory proteins, including splicing enhancers and silencers (i.e., heterogeneous nuclear ribonucleoproteins (hnRNPs) or serine/arginine-rich splicing factors (SRSFs))8.

MBNL proteins are key developmental regulators that are involved in different human diseases—e.g., myotonic dystrophy (DM)5,912 or Fuchs endothelial corneal dystrophy13. Interestingly, the MBNL1, MBNL2 and MBNL3 paralogs possess both redundant and unique functions in RNA processing and disease pathogenesis14. The best studied MBNL function is alternative splicing regulation5,11,12,15. All paralogs recognize RNA targets through an RNA-binding domain that contains four zinc fingers (ZF) organized into two tandems11. The MBNL-binding RNA motif is specified as a 5′-YGCY-3′ sequence (Y represents a pyrimidine)16,17 with preferentially single-stranded pyrimidines18. Depending on the location of the MBNL-binding motifs, whether upstream or downstream of the alternatively spliced exon, MBNLs serve either as repressors or activators of alternative exon inclusion, respectively17,19. A similar mode of action was previously described also for RBFOXs20 and CELFs21. Although many functional MBNL-binding motifs within pre-mRNAs (e.g., Clcn1, cTNT, Atp2a1 and Mbnl1) have been well described, most remain unknown14,2225.

The last decade has introduced several technologies for high-throughput analysis of protein/RNA interactions, including MBNL/RNA21,26, especially cross-linking and immunoprecipitation combined with deep sequencing (CLIP-seq)27 with subsequent modifications: individual-nucleotide resolution (iCLIP)28 and photoactivatable ribonucleoside-enhanced (PAR-CLIP)29. In general, CLIP-seq is a multistep method that starts from the physical cross-linking of RBPs with RNA sequences in situ using UV light. The protein/RNA complexes are subsequently purified by immunoprecipitation and molecular mass-based separation. Eventually, short RBP-bound RNA fragments are high-throughput sequenced30,31, followed by data filtration. The obtained overlapped reads form CLIP-seq clusters, which are considered to be RBP-bound regions. This method generates an enormous amount of data, enabling deeper insight into the proteins’ regulatory mode of action but also provides a high percentage of non-functional RNA binding sites and/or false-positive results. Thus, the potential RNA targets and RBP-binding motifs must still be verified in individual tests.

Herein, we described a new verification strategy that uses antisense oligonucleotides (AONs) and highly redundant hybrid splicing minigenes as a genetic construct carrying an alternative exon as well as interchangeable MBNL-sensitive regulatory elements within an upstream intron. The strategy is designed for the rapid, simple, reproducible, and efficient determination of functional protein/RNA interactions based on CLIP-seq or other whole transcriptome experiments. It also allows evaluation of the regulatory properties of MBNL-binding sites. Moreover, we show that the hybrid minigenes can be used to reveal and elucidate potential crosstalk between different RBPs in the regulation of alternative splicing. This method was tested for MBNL-specific RNA-binding regions but could be applicable for other RBPs. Finally, we emphasize the usefulness of hybrid minigenes to study the efficacy of potential therapeutic agents for inhibiting the interaction between MBNLs and expanded CUG repeats (CUG exp) associated with myotonic dystrophy type 1 (DM1) development.

Results and Discussion

Two AON types effectively block functional MBNL/RNA interactions

First, we set out to establish the most effective strategy to block protein/RNA interactions. Thus, we designed several types of AONs that target a well-defined MBNL-binding region in the Atp2a1 transcript and tested their inhibitory properties in vitro and in cellulo. Atp2a1 pre-mRNA contains alternative exon 22 (ex22), which as confirmed by mutagenesis, is positively regulated by the binding of all three MBNL paralogs to two YGCY motif-containing regions (region #1 and #2) that are localized within intron 22, ~110 nucleotides (nt) downstream of ex22 (Fig. 1a,c)14,24. We confirmed the MBNL-dependent alternative splicing of ex22 by the silencing of both MBNL1 and MBNL2 (Fig. 1b). Because the efficiency of MBNL binding may be modulated by the RNA’s structure18, we determined the secondary structure for a 145-nt-long fragment of Atp2a1 RNA containing regions #1 and #2 through limited cleavage with two enzymatic probes that recognize single-stranded RNA32 (Fig. 1c, Supplementary Fig. S2a). We observed that both YGCY-rich regions were localized in the 5′-part of the semi-stable hairpin structure, surrounded by several internal loops (Fig. 1c).

Figure 1
Alternative splicing of Atp2a1 ex22 is MBNL dependent and efficiently distorted upon AON targeting of MBNL-binding regions. (a) A scheme illustrating the alternative splicing pattern of Atp2a1 ex22 in the presence (green) or absence (red) of MBNLs. Black ...

To elaborate the interaction of MBNL1 with crucial YGCY motifs as well as the capacity of AONs to inhibit MBNL1 in vitro, we used a filter binding assay (FBA). First, we confirmed the sensitivity and specificity of this assay for a few RNA fragments that have previously been described in the literature as targets of MBNL124,25,33. We did not observe any interaction of this protein with four negative control RNAs (RNA-Ctrl1-4), with or without YGCY motifs (Supplementary Fig. S1a–c). Second, we designed RNA-based AONs that selectively blocked either individual region #1 or #2 of Atp2a1-RNA or both simultaneously. We tested AONs with either a locked nucleic acid (LNA) or 2′-O-methyl (2′OMe) modification of the RNA structure with or without a phosphorothioated backbone (PS) and DNA-based AONs. The LNAs (LNA(-PS)#1 and #2) contained 10-nt residues and were complementary to individual regions #1 or #2, while the 2′OMe- and DNA-type AONs were 21-nt-long and covered both regions (2′OMe(-PS) and DNA) (Fig. 1c). Having performed the in vitro assay, we observed that the short LNA#2 did not prevent formation of MBNL1/RNA complexes, LNA#1 only slightly deteriorated them, and 21-nt-long AONs suppressed MBNL1/RNA complexes by approximately 8-fold (Fig. 1d, Supplementary Fig. S2b). Consistently, we observed diminished MBNL1 affinity to Atp2a1-RNA mutants with nucleotide substitutions in the YGCY motifs within regions #1 and #2 (Fig. 1e), confirming their previously described functional significance24. The lack of complete inhibition of complex formation suggests binding of MBNL1 to other YGCY motifs present within this RNA, but with significantly lower affinity. To investigate this hypothesis, we used DNA-based AONs and applied mutagenesis. We found another YGCY motif upstream of region #1 that was important for MBNL1 binding in vitro (Supplementary Fig. S2c–e). We showed that short LNAs were the least effective in vitro, most likely due to covering only a part of the motifs bound by MBNL1.

Next, we assessed the inhibitory potential of the same RNA-based AONs on MBNL-dependent alternative splicing of ex22. First, we co-transfected cells with the Atp2a1 minigene, which encompasses a pre-mRNA sequence from exons 21 to 23 (Atp2a1WT), and the MBNL1-overexpressing vector. RT-PCR analysis showed substantial MBNL1-dependent enhancement of alternative ex22 inclusion (Fig. 1f,g). With the addition of different Atp2a1-specific AONs to this system, we observed almost complete inhibition of ex22 inclusion in LNA-PS#1- and 2′OMe-PS-treated cells as well as a significant change in LNA-PS#2. All AONs without the PS modification revealed no inhibitory effect on ex22 regulation (Fig. 1g). Moreover, the impact of 2′OMe-PS on repression of ex22 inclusion was observed even at the low 25-nM concentration (Fig. 1g). Importantly, for both LNA-PSs, but not for 2′OMe-PS, we observed a strong effect on three other MBNL-dependent alternative exons (Supplementary Fig. S2f). We expect that this effect may have been caused by LNA-PSs due to the relatively short sequence length and possible binding to a prevalent MBNL-binding motif present in many other transcripts.

In summary, we defined the structural features of the MBNL1-binding regions within Atp2a1-RNA. We demonstrated that the use of AONs in vitro, regardless of their chemistry, was an efficient tool to define the best MBNL-binding motifs. However, for in cellulo assays, the type of chemical modification is important. Both parameters—the length and chemical modification of 2′OMe-PS—determine its efficacy to inhibit MBNL/RNA complex formation, consistent with previously published results that showed the applicability of 2′OMe-PS AONs for blocking many different cis-regulatory RNA elements, including intron-exon junctions or mutation-induced alternative splice sites3437. Hence, the 2′OMe-PS type was chosen for further experiments.

AONs indicate functional MBNL-binding regions within introns but not exons

To confirm the applicability of AONs for the verification of RBP/RNA interactions, we selected five additional pre-mRNAs, besides Atp2a1, with potential MBNL-binding motifs within an intronic sequence downstream or upstream of Pphln1 ex6 and NASP ex7, respectively, as well as within exonic sequences of ex10 of Ldb3, ex7 of Nfix and ex1 of Mbnl1 (Fig. 2a). They were selected based on MBNL-specific CLIP-seq data deposited in MBNL Interactome Browser (MIB.amu.edu.pl)14. We confirmed their MBNL-dependent alternative splicing in cells upon MBNL1,2 silencing (Fig. 2b). To date, functional MBNL-binding motifs have been well defined for three pre-mRNAs, Atp2a1, Nfix and Mbnl1 19,24,38; however, these motifs remain unknown for the other selected transcripts. We established two criteria to emerge the most probable MBNL-binding motifs in pre-mRNA: (i) the presence of an MBNL-dependent alternative exon adjacent to putative binding motifs with CLIP-seq clusters either within the exon or upstream or downstream intron up to 250 nt from the exon; (ii) overlapping of at least three YGCY sequence motifs that are at least partially conserved in human and mouse.

Figure 2
AONs indicate functional MBNL-binding regions within introns but not exons. (a) Schematic representation of the alternative splicing patterns of MBNL-dependent exons from Atp2a1, Pphln1, NASP, Nfix, Ldb3 and Mbnl1 pre-mRNAs, which depend on the localization ...

For each selected transcript, the identified CLIP-seq clusters covered three or more YGCY motifs, and in some instances, their number reached up to 15. First, to specify their importance in MBNL1 binding, we generated ~100- to 200-nt-long intronic (Pphln1-, NASP-) and exonic (Nfix-, Ldb3-, Mbnl1-) RNA fragments and designed AONs that were complementary to these regions (Mbnl1-RNA described in38) (Supplementary Fig. S3a). In FBA, we observed that certain AONs, by blocking specific RNA fragments, significantly deteriorated the MBNL1 affinity, indicating one (within Pphln1-, Atp2a1-, NASP-RNAs) or two (within Nfix-, Ldb3-RNA) regions composed of a string of YGCY motifs as the most essential for MBNL1/RNA interactions (Fig. 2c and Supplementary Fig. S3b). In the case of Nfix and Ldb3, for further in cellulo studies, we selected AONs that bound to exonic sequences and showed the strongest regulatory potential.

To confirm the functionality of the selected YGCY motifs that are essential for binding, we introduced 2′OMe-PSs into cells at 125 nM. Subsequently, we used RT-PCR to analyze the alternative splicing pattern of targeted endogenous pre-mRNAs. AONs that target intronic sequences induced significant changes in alternative exon inclusion. The Atp2a1- and Pphln1-specific 2′OMe-PSs considerably suppressed ex22 and ex6 inclusion, respectively, whereas 2′OMe-PS, which is specific for NASP, significantly induced inclusion of ex7 (Fig. 2d). In those transcripts, the analyzed YGCY motifs were located in downstream (Atp2a1 and Pphln1) or upstream (NASP) introns and induced MBNL-dependent alternative exon promotion or repression, respectively. In each case, the direction and strength of alternative splicing changes upon AON application were similar to the effect of siRNA-mediated MBNL1,2 silencing (compare Fig. 2b and d).

We next sought to identify whether targeting MBNL-binding regions with specific 2′OMe-PS in MBNL-repressed exons of Nfix, Ldb3 and Mbnl1 would also trigger the same effect as siRNA against MBNL1,2 and lead to their enhanced inclusion. Unexpectedly, we observed the opposite effect, and found that the inclusion of ex7, ex10 and ex1, respectively, was significantly repressed by specific AONs (Fig. 2d). Silencing of MBNL1 and 2 and AON application induced the opposite effect on the inclusion of the analyzed exons. One possible explanation for this phenomenon is that AONs, due to their interaction within the exons of their targeted pre-mRNAs, may affect the binding of other splicing modulating factors, including splicing enhancers.

We can infer that DNA oligomers are an efficient tool to screen MBNL-binding regions in vitro because DNA and 2′OMe-PS AONs exert comparable inhibitory properties. On the other hand, only 2′OMe-PSs indicate functional intronic MBNL-binding regions in cells. However, the strength of the AON-induced change in alternative splicing strongly depends on the primordial distribution of the splicing isoforms and potency of MBNLs to regulate particular alternative exons39. Moreover, we encountered difficulties in analyzing all three MBNL-binding regions within exons where AONs induced exon skipping instead of the anticipated exon inclusion.

It remains unclear what mechanism drives alternative exon regulation by MBNL proteins bound to individual RNA cis-elements. Two previous works proposed involvement of MBNLs in the spliceosome formation via interacting with U2 auxiliary factor 65 kDa subunit (U2AF65) responsible for 3′ splice site definition. Depending on the binding site localization within introns, either downstream or upstream of alternative exon, MBNLs may play a role as an enhancer for U2AF65 binding40 or its competitor by modifying the RNA secondary structure41, respectively. The other possibility is that MBNLs associated with RNA affect binding of other trans-factors such as CELF142 and RBFOX43.

Analogously, the binding of MBNLs to intronic cis-elements tested in this study could affect U2AF65 recruitment. Therefore, AONs blocking the RNA/MBNL interaction may contribute indirectly to observed alternative splicing changes. On the other hand, binding of AON itself could directly disrupt spliceosome organization via RNA structure rearrangements. However, due to a relatively long distance between MBNL-binding sites and alternative exons (~110–270 nt) it seems to be less possible. Blocking intronic or exonic MBNL-binding sites by AONs might also interfere with binding of other trans-factors pivotal for regulation of the alternative exon inclusion. Exon skipping induced by AON targeting either the 5′ and 3′ splice sites and/or exonic splicing enhancers (ESEs) has often been reported in studies on splicing manipulation in genetic, aberrant splicing-based disorders, including Duchenne Muscular Dystrophy (DMD)44. Deutekom and others showed that utilizing a set of AONs that cover many regions along with an exonic sequence leads to exon exclusion45.

Highly redundant hybrid Atp2a1 minigenes confirm the functional MBNL-binding motifs in intronic and exonic sequences

Previous observations led us to design hybrid minigenes as an alternative and complementary tool to test the sensitivity of RNA regulatory elements to MBNLs. To prepare the hybrid minigenes, we removed a natural 111-bp-long MBNL-binding cassette, which contains regions #1 and #2 with YGCY motifs, from intron 22 of the Atp2a1WT minigene (Atp2a1Δ). Removal of this cassette resulted in a strong reduction of the ex22 splicing response to MBNL1 overexpression (Fig. 3a). A similar effect was observed when we replaced the MBNL-binding cassette with a sequence that lacked YGCY motifs (Atp2a1Δ-Ctrl) (Fig. 3a). Subsequently, the studied RNA sequences from Pphln1, NASP, Nfix, Ldb3 and Mbnl1 transcripts, which contained the analyzed MBNL-binding motifs, were inserted into the Atp2a1Δ minigene at the site of the deleted MBNL-sensitive cassette (Fig. 3b and Supplementary Fig. S3a). The sequences were cloned in a way to preserve their autonomous RNA secondary structures and reduce the potential effect of neighboring sequences on the generated RNA structure. For that purpose, the acceptor site in Atp2a1 minigene, which constituted a naturally stable helical region derived from intron 22 within pre-mRNA, was slightly extended by a short artificial helix which was designed in a way to not affect the secondary structure of the MBNL-binding sites (Fig. 3b). To better understand the effect of the RNA structure of the MBNL-binding regions on MBNLs activity, we experimentally determined the secondary structures of short intronic (Pphln1-, NASP-) and exonic (Nfix-, Ldb3-, Mbnl1-) RNA fragments representing the sequences inserted into the hybrid minigene, as described above for Atp2a1-RNA (Fig. 3c and Supplementary Fig. S4). RNA structure probing experiments showed that the significant MBNL-binding motifs, depicted in in vitro assays upon AON application, were predominantly located within semi-stable hairpin structures, either as strings of multiple YGCY motifs placed on one side of the hairpin structure with several unpaired nucleotide residues (Ldb3-RNA, Mbnl1-RNA) or within partially single-stranded regions (Pphln1-RNA, NASP-RNA). Only in Nfix-RNA the predicted MBNL-binding motifs were located within a stable hairpin structure with two symmetrical internal loops that were not recognized by any of the enzymatic structure probes.

Figure 3
Hybrid Atp2a1 minigenes confirm the functional intronic and exonic MBNL-binding regions. (a) Percentage of alternative ex22 inclusion in Atp2a1WT and Atp2a1Δ mRNA, lacking a fragment containing MBNL-binding regions, upon MBNL1 overexpression with ...

Next, we co-transfected HeLa cells with one of five obtained minigenes, Atp2a1Δ-Pphln1, Atp2a1Δ-NASP, Atp2a1Δ-Nfix, Atp2a1Δ-Ldb3 and Atp2a1Δ-Mbnl1, and the MBNL1 overexpressing vector. As anticipated, we observed that for all of the precursor RNAs synthesized from hybrid minigenes, inclusion of ex22 was promoted by MBNL1, similar to that for the original Atp2a1WT pre-mRNA (Fig. 3a,d; green bars). For two minigenes (Atp2a1Δ-Mbnl1 and Atp2a1Δ-Ldb3), the endogenous MBNLs already strongly elevated ex22 inclusion compared with Atp2a1WT (Fig. 3d; white bars). For cells transfected with Atp2a1Δ-Nfix, we observed an additional artificial splicing isoform due to the presence of the remaining 5′ splice site within the cloned Nfix exon 7 fragment (Fig. 3d, Supplementary Fig. S4c). However, MBNL1 overexpression revealed strong inclusion of the Atp2a1 exon 22-containing isoform (Fig. 3d).

In cells that were additionally transfected with AONs that targeted specific MBNL-binding regions, we observed a reduction of the ex22 inclusion, consistent with the effect triggered by 2′OMe-PS in Atp2a1WT pre-mRNA (Fig. 3a,d; red bars). In most cases, upon AON usage, the decreased level of ex22 inclusion did not reach the level observed in Atp2a1Δ or Atp2a1Δ-Ctrl mRNAs (Fig. 3a,d). We suppose that this effect was caused by blocking only a single MBNL-binding region with one AON, whereas the remaining motifs could still recruit MBNLs, as we observed in in vitro assays, and had a slight impact on ex22 inclusion.

Currently, RBP/RNA interaction studies concerning alternative splicing regulators employ a minigene preparation established on a transcript of interest containing an RBP-regulated alternative exon and RBP-binding region with its mutated variants19,46. Additionally, the inconvenience of the distribution of splicing isoforms is a limiting parameter. The length of the intronic sequences might also make preparations difficult47. To verify the high-throughput data, several of such minigenes would need to be provided, extending the time of study. Moreover, AON application is limited to intronic regulatory elements because targeting exons that are abundant in cis-acting regulatory sites leads to unexpected splicing misregulation.

Here, we present a new approach based on a hybrid minigene composed of an unchangeable core with an alternative exon regulated by MBNLs and exchangeable analyzed RNA regions containing potential MBNL-binding motifs combined with specific AON treatment. Of note, while we decided to use AONs, mutagenesis of potential MBNL-binding sites in RNA could be applied instead. AON application provides us with rapid and reproducible results for many intronic- and exonic-derived regulatory regions as well as the ability to evaluate their regulatory properties. Despite unexpected complications with AON usage upon potential MBNL-binding sites verification in endogenous exonic regions we decided to proceed with experiments with AONs on hybrid minigenes background as a consequence of AON application at each step of the study from in vitro to in cellulo.

Our observations clearly show that regulatory regions transferred from the original context into a different transcript may still act as cis-regulatory elements and regulate alternative splicing according to general principles. Our observations also indicate that MBNLs are sensitive to each of the analyzed intronic or exonic RNA fragments. Moreover, these experiments revealed that a sequence that was primarily located within an exon and acted as an ESE, when it was moved into an intronic context, became an MBNL-dependent intronic splicing enhancer (ISE). This result sheds light on the question regarding the actual mechanism of MBNL-dependent exon repression. We hypothesize that MBNLs, when bound to exonic cis-elements, can affect the binding or activity of other trans-factors that act as alternative splicing enhancers. This may explain the perplexing splicing effects that we observed when testing AONs that targeted the exonic sequences of Nfix, Ldb3 and Mbnl1 pre-mRNAs (Fig. 2d). We showed that the hybrid minigene-based approach is a useful tool to analyze MBNL-binding regulatory elements and, with great probability, that it can be successfully applied to test the functionality of other RBP-bound cis-elements that are naturally located in any parts of precursor or mature forms of different RNA classes. Finally, the developed hybrid minigene assay, by providing an indiscrete background, may be applicable to compare the quality of different sequences that contain MBNL-binding regions regarding the number and localization of YGCY motifs.

Potential crosstalk between SRSF1 and MBNLs in the regulation of alternative splicing

Blocking the exonic regions of interest with complementary AONs may lead to the unintended interruption of the general splicing machinery activity but also other trans-acting factors, including a large group of splicing regulators, e.g. SRSFs or hnRNPs. We decided to partially elaborate this issue. First, we attempted to find potential splicing factors that were able to bind near the MBNL-binding region using in silico prediction software, including ESE finder and SF Map 48,49. Based on these algorithms and published data5053, we anticipated that the SRSF1 protein would be a putative regulatory factor, which binds close to the exonic MBNL-binding regions tested in this study and be impeded by the examined AONs (Fig. 4a). Using an in vitro electrophoretic mobility shift assay (EMSA), we demonstrated that recombinant SRSF1 bound to the studied exonic Mbnl1-RNA and Nfix-RNA with high affinity, ranging from 13 to 60 nM, respectively (Fig. 4b), compared with negative control RNAs (CAG)20 and (AGG)20 (Supplementary Fig. S5). The use of 2′OMe-PS-Mbnl1 and 2′OMe-PS-Nfix in in vitro tests significantly deteriorated the affinity by 2 to 3 fold (Fig. 4b).

Figure 4
Potential crosstalk between SRSF1 and MBNLs. (a) Experimentally determined secondary structures of Mbnl1-RNA and Nfix-RNA with in silico-predicted SRSF1 binding regions marked with blue boxes48,49. 2′OMe-PS AONs blocking MBNL-binding regions are ...

To further investigate the potential mechanism of competition between SRSF1 and MBNLs in cellulo, we tested the alternative splicing of ex1 of the Mbnl1 fragment within the artificial Atp2a1 minigene pre-mRNA (Mbnl1 minigene). Overexpression of MBNL1 led to the exclusion of ex1 (Fig. 4c), while titration of SRSF1 in the MBNL1 background progressively promoted ex1 inclusion (Fig. 4c). The results for the pre-mRNA of Mbnl1Mut minigene with MBNL-binding motif mutations within ex1 showed only slightly distorted activity of SRSF1 (Fig. 4c). We observed similar but weaker effects of SRSF1 activity on the alternative ex7 inclusion level in mRNA of the NfixWT minigene and its variant with a mutated exonic YGCY motif - NfixMut (Fig. 4d).

These results suggest that SRSF1 and MBNLs are antagonistic splicing regulators of ex1 of Mbnl1 and ex7 of Nfix pre-mRNAs. SRSF1 very likely interacts in the vicinity of but not within MBNL-binding motifs because mutations of YGCYs do not strongly affect its activity. Potentially, binding of the tested AONs may block SRSF1 binding sterically or via RNA structure alterations, resulting in repression of the targeted exons. Additional studies are required to elucidate the precise mechanism and interplay between these two splicing regulators.

To date, only a few mechanisms of MBNL-mediated alternative exon regulation that implicate other trans-acting factors have been proposed4042. Although none of them is able to explain the MBNL-mediated regulation of alternative splicing through interactions within an exonic region, we can deduce that the mode of action of MBNLs involves direct competition of two proteins for the same binding region, as described for U2AF6541, or indirect competition by the modulation of the RNA secondary structure and/or assistance of mediatory proteins, as shown for U2AF6540 and CELF142. Our initial results seem to support the latter mode of action; however, this finding needs to be clarified with more data.

The hybrid Atp2a1 minigene is a useful tool to characterize inhibitors of adverse MBNL/RNA interactions

To emphasize the versatility of the Atp2a1 hybrid minigene, we determined its usefulness for screening or characterizing the potency of different reagents that distort pathogenic protein/RNA interactions in myotonic dystrophy type 1 (DM1) or Fuchs endothelial corneal dystrophy.

DM1 is a neuromuscular, autosomal dominant disease that is caused by the expansion of three-nucleotide CTG repeats located in the 3′-untranslated region of the myotonic dystrophy protein kinase gene (DMPK)5456. Expression of mRNA with CUG expansion ((CUG)exp) leads to mRNA retention in the nucleus as well as pathogenic recruitment and sequestration of nuclear proteins, including MBNLs, to an RNA hairpin-like structure formed by the repeats55. The longer the repeats, the more severe the missplicing of hundreds of genes due to the functional insufficiency of MBNLs57. On the other hand, in Fuchs endothelial corneal dystrophy, toxic (CUG)exp RNA repeats occur within intron 2 of a transcription factor 4 pre-mRNA (TCF4)13,58.

Among the therapeutic strategies aimed at ameliorating the toxic effect of (CUG)exp, antisense oligonucleotides and small compounds have been frequently employed to specifically bind to repeats and prevent MBNL sequestration5962. We have previously shown that an 8-nt-long oligonucleotide composed of LNA-PS moieties (LNA-PS-CAG-8)63 and erythromycin (EM)64 prevent MBNL sequestration on this toxic RNA by complementarily hybridizing to or potentially binding to U/U mismatches within the structure formed by (CUG)exp, respectively. These molecules diminish adverse molecular outcomes, mainly abnormalities in alternative splicing in the cell and mouse models of DM1.

To investigate the usefulness of the hybrid minigene in the screening of potential therapeutics that target CUG repeats, we substituted a natural regulatory cassette of Atp2a1 with an MBNL-binding region composed of 17 CUG repeats (CUG)17 (Atp2a1Δ-(CUG) 17) (Fig. 5a). Our previous experiments showed that this type of sequence forms a stable RNA hairpin structure that binds all MBNLs with high affinity14. In this study, MBNL1 overexpression induced a strong splicing response of ex22 in the minigene’s pre-mRNA (Supplementary Fig. S6a). Additionally, we assumed that more than one MBNL1 molecule binds to the pre-mRNA of Atp2a1Δ-(CUG) 17. In support of our hypothesis, hybrid minigenes expressing the pre-mRNAs containing (CUG)4 or (CUG)8 undergo MBNL-mediated splicing with lower rate of ex22 inclusion compared to Atp2a1Δ-(CUG) 17 (Supplementary Fig. S6b).

Figure 5
The hybrid minigene is useful to screen potential RNA-binding therapeutics. (a) A scheme illustrating MBNL-dependent ex22 inclusion to mRNA derived from the Atp2a1Δ-(CUG) 17 minigene by extensive MBNL1 binding to the hairpin structure formed by ...

Next, we chose LNA-PS-CAG-8 and EM as examples of efficient inhibitors of the MBNL/CUG interaction and used them in our minigene assay. Cells co-transfected with the Atp2a1Δ-(CUG) 17 minigene and MBNL1 overexpressing vector were treated with different concentrations of either LNA-PS-CAG-8 or EM. We observed a strong and gradual decrease in ex22 inclusion induced by LNA-PS-CAG-8 but not by the control LNA oligonucleotide, reaching below the level established by endogenous MBNLs at a concentration of 125 nM (Fig. 5b). The EM showed a weaker effect on ex22 inclusion over a broad range of this antibiotic concentration (Fig. 5c). This result was consistent with our previous findings that showed that these two compounds have different potencies as inhibitors of the MBNL/(CUG)exp interaction in both in vitro and in vivo models63,64.

These results show that the Atp2a1Δ-(CUG) 17 hybrid minigene is a very sensitive tool for characterizing different MBNL/(CUG)exp inhibitors and that after certain modifications, such as reporter gene inclusion, the hybrid minigene can be successfully applied in high-throughput screening. A related screening system, based on the detection of alternative splicing pattern changes within the Clcn1 minigene’s pre-mRNA and including luciferase system for high-throughput analysis, has been described previously65. The advantage of our Atp2a1Δ-(CUG) 17 minigene is its sensitivity, reproducibility and simplicity because it can be introduced into non-DM1 cell models. Moreover, the assay provides not only qualitative but also quantitative information about the potency of the studied compounds and additionally enables to monitor the differences in the number of MBNLs associated with CUG repeats. Investigation of potential therapeutic agents for diseases mediated by toxic RNA that disrupts the activity of RBPs, including myotonic dystrophies, is an ongoing process. Our assay could facilitate the screening of molecules on in vitro stages.

Methods

Oligonucleotides

All of the DNA sequences were purchased from oligo.pl® (Institute of Biochemistry and Biophysics PAN, Warsaw, Poland) and are listed in Supplementary Tables. All RNA-based AONs were synthesized by RiboTask™ and are listed in Table 1.

Table 1
RNA-based AON sequences.

Plasmid preparation

To obtain the Atp2a1WT minigene, a fragment of the Atp2a1 gene between exons 21 and 23 containing MBNL-sensitive alternative exon 22 was amplified from mouse genomic DNA using Platinum® high fidelity Taq DNA polymerase (Invitrogen™) according to the manufacturer’s protocol with a SrcMres_F/SrcMres_R primer set (Ta = 55 °C) whose sequences are provided in Supplementary Table S1. These primers introduced unique restriction sites for XhoI and BamHI. To obtain the Atp2a1Δ minigene, a 111-bp sequence within intron 22 in the Atp2a1WT minigene that included the MBNL-binding regions was substituted with a 34-bp linker sequence containing unique restriction sites for NotI and SalI. First, two fragments of the final Atp2a1Δ insert were amplified using the pEGFP_F/NotSal_R and NotSal_F/pEGFP_R primer sets (Ta = 60 °C) to introduce the 34-bp linker in both PCR products. Second, based on their complementarity to 34-nt linker, the obtained PCR fragments constituted the template for PCR with the pEGFP_F/pEGFP_R primer set (Ta = 60 °C) to provide a full-length Atp2a1Δ sequence. To obtain Atp2a1-hybrid minigenes, the sequences of interest from the Pphln1, NASP, Nfix, Ldb3, Mbnl1 and Ctrl (Capzb) genes were amplified from human (NASP) or mouse (others) genomic DNA with the Pph1insF/Pph1insR, NASPinsF/NASPinsR, NfixinsF/NfixinsR, Ldb3insF/Ldb3insR, Mbnl1insF/Mbnl1insR, CTRLinsF/CTRLinsR primer sets (Supplementary Table S1), respectively. The primers introduce restriction sites for NotI or SalI. They also contained 5 additional nucleotides at the 5′ ends to introduce a hairpin structure in transcribed pre-mRNAs to stabilize the secondary structure of the fragments of interest (except for -Mbnl1 construct). To obtain the Atp2a1-(CUG) 17 minigene, oligodeoxynucleotides CTG17F and CTG17R with restriction sites for either NotI or SalI, were used. Prior to their hybridization for one hour at RT, they were purified on a denaturing 10% polyacrylamide (PA) gel, followed by precipitation and denaturation at 95 °C for 5 min. All of the amplified DNA fragments of interest were ligated into the pEGFP-C1 vector (CloneTech) prior to transformation into DH5α bacteria cells. To obtain the Mbnl1 minigene, a DNA sequence including the 3′ part of the intron (53 bp) and 5′ part of exon 1 (110 bp) of the Mbnl1 gene was amplified from human genomic DNA using the Mbnl1F/Mbnl1R primer set (Ta = 55 °C), introducing restriction sites for NotI or SalI (Supplementary Table S1). A Mbnl1Mut minigene was prepared in two rounds of PCR. First, two products were amplified with primers that introduced point mutations within the YGCY motifs (Mbnl1mtR/Mbnl1F as well as Mbnl1mtF/Mbnl1R; Supplementary Table S1) (Ta = 55 °C) and were purified on an agarose gel. Second, the purified PCR products were annealed and extended in 4 cycles of 92 °C for 2 min, 55 °C for 2 min, 72 °C for 2 min, and then, an Mbnl1F/Mbnl1R primer set that induced the restriction sites for NotI or SalI was added and the reaction proceeded according to the manufacturer’s protocol at Ta = 55 °C. The obtained final PCR products, after digestion with NotI or SalI, were ligated into the Atp2a1Δ minigene and were transformed into DH5α bacteria cells. The pEGFP-C1-MBNL1-41 vector for MBNL1 overexpression was previously described38. pEGFP-SF2 (pEGFP-C1-SRSF1) was a gift from Dr. Tom Misteli (Addgene plasmid # 17990)66.

Cell culture and transfection

Human HeLa and mouse C2C12 cells were grown in high-glucose DMEM medium (Lonza) supplemented with 10% fetal bovine serum (Sigma) and 1x antibiotic/antimycotic (Sigma). Human skeletal myoblast (HSkM) cells were grown in HAM F-10 medium (Sigma) supplemented with 20% FBS, 1x antibiotic/antimycotic, 0.39 µg/ml dexamethasone (Sigma) and 10 ng/ml epidermal growth (Sigma). All cells were grown at 37 °C and in a 5% atmosphere of CO2. HeLa, C2C12 or HSkM cells plated in 12-well plates were transfected at 50–60% confluence with Lipofectamine® 2000 (Invitrogen™) according to the manufacturer’s protocol. Single transfection was conducted with an siRNA mix against MBNL1 and MBNL2 (25 nM each) (FUTURE synthesis and RiboTask™, respectively67,68), 50 nM AllStars negative control siRNA (Qiagen), or a specific AON at 125 nM, in which AON-Ctrl was 2′OMe-PS unspecific to a tested transcript. Co-transfection was conducted with 200 ng of the minigene and 500 ng (or as indicated in the figures) of the MBNL1, SRSF1 or GFP expressing vector. For verification of the MBNL-binding regions and inhibition of the MBNL/(CUG)exp interaction, the co-transfection was followed by a 4-hour incubation and transfection with selected AONs. Erythromycin was added directly to the medium. The cells were harvested 48 hours after transfection.

Splicing analyses of mature mRNA

Total RNA was isolated from cells using TRI-reagent (Sigma) according to the manufacturer’s protocol. cDNA was synthesized using GoScript™ Reverse Transcriptase (Promega) with Random Primers (Promega) according to the manufacturer’s protocol. RT-PCR was performed using GoTaq® Flexi DNA Polymerase (Promega) with the primer sets listed in Supplementary Table 1 at Ta = 55 °C. The PCR products were electrophoretically separated in 1–2% agarose gels containing 0.005% ethidium bromide, and images were captured using G:Box EF2 (Syngene). In the main figures, splicing analyses are represented by cropped sections of the original gels separated by black lines. All of the raw images of the RT-PCR analyses are shown in Supplementary Fig. 7.

Preparation of radiolabeled RNA fragments

The templates for the transcription reactions of RNA fragments were obtained in two rounds of PCR. In the first PCR, longer products were amplified with genomic mouse or human DNA templates using specific _F/_R primer sets (the primer sequences and annealing temperatures (Ta) are listed in Supplementary Table S2). The obtained PCR products constituted a template for a second round of PCR with specific _TF/_TR primer sets harboring a promoter for polymerase T7 (Supplementary Table S2) at Ta = 55 °C. Templates for Atp2a1-RNA mutants were prepared in two rounds of PCR similar to that for the Mbnl1Mut minigene. In the first step, specific Atp2a1mt_F/Atp2a1_TR and Atp2a1mt_R/Atp2a1_TF were used. In the second round of PCR, only _TF and _TR were used. The transcription reaction was performed in 50 µl containing 10 µl of DNA template (~0.5 μg), 0.15 mM of each ribonucleotide (Invitrogen™), 0.45 mM guanosine (Sigma-Aldrich), 50 U of T7 RNA Polymerase (Ambion), 1 × T7 transcription buffer (Ambion), and 40 U of RNasin®Plus RNase Inhibitor (Promega). The transcripts were purified on a denaturing 8% PA gel (19:1 acrylamide:bisacrylamide), followed by ethanol precipitation. For 5′-end radiolabeling, 2 pmol of RNA was incubated with 2 pmol (12 mCi) of [γ-P32] ATP, 1 U of RNasin®Plus RNase Inhibitor (Promega) and 10 U of OPTI Kinase (Affymetrix) in 1 x reaction buffer (Affymetrix) at a total volume of 10 µl and at 37 °C for 45 min. The 5′-32P-labeled RNAs were subsequently run on a denaturing 8% PA gel. The bands of RNAs were visualized via Storage Phosphor Screen BAS-IP (IP) and a laser scanner FLA-1500 (FujiFilm) and were then excised, followed by ethanol precipitation and resuspension in 20 µl of double-distilled water.

Chemical and enzymatic analysis of RNA structure

Analysis was conducted as previously described38 with slight changes. Briefly, 5′-32P-labeled RNA was first subjected to a denaturation and renaturation procedure in either buffer N (20 mM Tris-HCl pH 7.2, 80 mM NaCl, 2 mM MgCl2) for ribonucleases T1 and T2 or in a commercial S1 buffer (Fermentas) for endonuclease S1. Limited RNA digestion was initiated by mixing 5 µl of the RNA sample (~0.5 pmol) with 5 µl of a probe solution containing S1 and T2 at the concentrations indicated in Supplementary Figs S2a and S4a. An equal volume of stop solution was added to stop all reactions. The products of cleavage were separated on a denaturing 10% PA gel along with the nucleotide ladders constituting products of alkaline hydrolysis (F), lead ion cleavage (Pb) and T1 nuclease digestion (T1L). The F ladder was generated by RNA cleavage in formamide at 99 °C for 10–15 min. The T1L ladder was generated by RNA cleavage in 50 mM sodium citrate pH 4.3 and 7 M urea by addition of 10 or 15 U/µl of T1 at 55 °C for 10 min. The Pb ladder was generated by RNA cleavage in buffer N by 0.25 mM of Pb2+ at 55 °C for 2.5 min. The bands of RNAs were visualized via IP and the laser scanner FLA-1500 after overnight (O/N) exposition. In silico prediction of the secondary structure was performed using the mfold program with experimentally defined constraints.

Recombinant proteins

The GST fusion construct with a truncated 41-kDa MBNL1 isoform sequence encoded by exons 1–4 of the MBNL1 gene with a His6 tag at the C-terminus was prepared as previously described69.

To generate the construct for recombinant SRSF1, 558 bp of the SRSF1 coding sequence was amplified using the pEGFP-SF2 vector (Addgene) as a template and SRSF1_F/ SRSF1_R primer set (Supplementary Table S2) and was cloned into the pRSF-Duet vector using BamHI and NotI. Sequencing of the obtained construct was followed by transformation of the E. coli BL21(DE3)pLysS strain (Novagen). Production of 23-kDa SRSF1 containing a His6 tag at the C-terminus was performed as previously described70.

Quantification of the MBNL1/RNA interaction and its inhibition by AONs in vitro

The filter binding assay (FBA) was performed to assess the affinity of MBNL1 to different RNAs. 5′-32P-labeled RNAs (0.05 nM) were subjected to a denaturation and renaturation procedure by heating the samples at 95 °C for 1 min followed by a 10-min incubation at RT. Subsequently, the RNAs were incubated with the indicated protein concentrations (ranging from 0 to 200 nM) in buffer FB (250 mM NaCl, 15 mM KCl, 50 mM Tris-HCl pH 8.0, 0.05% Tween-20, 1 mM MgCl2) at 37 °C for 15 min. Studying the inhibitory property of AONs, 0.05 nM of 5′-32P-labeled RNAs mixed with 0.5 µM of RNA-based AONs or 20 µM of DNA-AONs (Supplementary Table S3) were subjected to the denaturation and renaturation procedure, followed by incubation at 37 °C for 15 min. Next, the indicated concentrations of MBNL1 (ranging from 0 to 200 nM) were added to each sample, followed by incubation at 37 °C for 15 min. Next, 25 µl of each sample was loaded onto the filter binding apparatus with nitrocellulose (Protran BA 85, Whatman®) and nylon (Hybond™ N + , Amersham) membranes that were previously wetted in buffer FB. The signal from the membranes was visualized via IP and laser scanner FLA-1500 after O/N exposition. The dissociation constant (Kd) of the MBNL1/RNA complexes treated or non-treated with different AONs was calculated in the GraphPad program using the following equation: one site specific binding curve (Y = Bmax*X/(Kd + X)).

Quantification of the SRSF1/RNA interaction and its inhibition by AONs in vitro

The electrophoretic mobility shift assay (EMSA) was carried out by incubation of 0.05 nM of 5′-32P-labeled RNA fragments with the indicated SRSF1 concentrations (ranging from 0 to 800 nM). The reactions were performed in a volume of 10 µl in buffer A (100 mM NaCl, 20 mM HEPES-Na pH 8.0, 5% glycerol, 0.5 mM DTT, 0.2 mM EDTA, 50 µg/ml BSA (Invitrogen™)) at 37 °C for 20 min. To identify SRSF1-binding regions, 0.5 µM of 2′OMe-PS-Mbnl1 or -Nfix along with 0.05 nM of 5′-32P-labeled RNAs were subjected to denaturation and renaturation, followed by incubation at 37 °C for 20 min in buffer A. The samples were mixed with loading buffer (30% glycerol, 0.25% of bromophenol blue and xylene cyanol) and run on a non-denaturing 8% PA gel. The gel was subsequently dried, and the signal was visualized via IP and the laser scanner FLA-1500 after O/N exposition. The Kd of the SRSF1/RNA interaction was calculated based on the signal of free RNA and using the equation: one phase decay curve equation (Y = (Y0  Plateau)*exp(−K*X) + Plateau) in Graph Pad program.

Statistical analysis

Group data obtained in vitro and in cellulo are expressed as the means ± standard deviation (SD). The statistical significance of the RT-PCR and EMSA results was determined by two-tailed Student’s t-test using Microsoft Excel (*P < 0.05; **P < 0.01 and ***P < 0.001). Statistical analysis was calculated using 2–4 biological repeats. Similar results were obtained from at least two independent experiments.

Data availability

All data generated or analyzed during this study are included in this published article (and its Supplementary Information files).

Electronic supplementary material

Acknowledgements

The Nfix and NfixMut minigenes were gifts from M. Ares19. (CAG)20 and (AGG)20 RNA sequences were gifts from W. Krzyżosiak. We thank D. Zielińska for Atp2a1Δ-(CUG) 4 and Atp2a1Δ-(CUG) 8 minigenes preparation. Funding: Foundation for Polish Science TEAM program cofinanced by the European Union within the European Regional Development Fund [TEAM/2011-7/10 to KS]; Polish National Science Centre [2011/01/B/NZ1/01603, 2014/15/B/NZ2/02453 to KS, 2014/12/T/NZ2/00516 to ŁJS, 2017/24/C/NZ1/00112 to KT]; National Multidisciplinary Laboratory of Functional Nanomaterials NanoFun [POIG.02.02.00-00-025/09]. Funding for open access charge: Ministry of Science and Higher Education of the Republic of Poland, from the quality promoting subsidy, under the Leading National Research Centre (KNOW) program for the years 2014–2019.

Author Contributions

Author Contributions

Conception and design of experiments: K.S., K.T., P.C. and Ł.J.S. Acquisition, analysis and interpretation of data: K.T. (all in vitro assays and in cellulo assays using Mbnl1 and Mbnl1Mut minigenes and Atp2a1Δ-(CUG) 17 hybrid minigene), P.C. (the rest of the in cellulo assays). Identification of MBNL targets using CLIP-seq data: P.C. and Ł.J.S. Drafting and revision of the manuscript: K.S., K.T., P.C. and Ł.J.S.

Notes

Competing Interests

The authors declare that they have no competing interests.

Footnotes

Piotr Cywoniuk and Katarzyna Taylor contributed equally to this work.

Electronic supplementary material

Supplementary information accompanies this paper at 10.1038/s41598-017-17816-x.

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

1. Sanchez SE, Petrillo E, Kornblihtt AR, Yanovsky MJ. Alternative splicing at the right time. RNA Biol. 2011;8:954–959. doi: 10.4161/rna.8.6.17336. [PMC free article] [PubMed] [Cross Ref]
2. Hallegger M, Llorian M, Smith CW. Alternative splicing: global insights. FEBS J. 2010;277:856–866. doi: 10.1111/j.1742-4658.2009.07521.x. [PubMed] [Cross Ref]
3. Nilsen TW, Graveley BR. Expansion of the eukaryotic proteome by alternative splicing. Nature. 2010;463:457–463. doi: 10.1038/nature08909. [PMC free article] [PubMed] [Cross Ref]
4. Wang ET, et al. Alternative isoform regulation in human tissue transcriptomes. Nature. 2008;456:470–476. doi: 10.1038/nature07509. [PMC free article] [PubMed] [Cross Ref]
5. Pascual M, Vicente M, Monferrer L, Artero R. The Muscleblind family of proteins: an emerging class of regulators of developmentally programmed alternative splicing. Differentiation. 2006;74:65–80. doi: 10.1111/j.1432-0436.2006.00060.x. [PubMed] [Cross Ref]
6. Jin Y, et al. A vertebrate RNA-binding protein Fox-1 regulates tissue-specific splicing via the pentanucleotide GCAUG. EMBO J. 2003;22:905–912. doi: 10.1093/emboj/cdg089. [PubMed] [Cross Ref]
7. Dasgupta T, Ladd AN. The importance of CELF control: molecular and biological roles of the CUG-BP, Elav-like family of RNA-binding proteins. Wiley Interdiscip Rev RNA. 2012;3:104–121. doi: 10.1002/wrna.107. [PMC free article] [PubMed] [Cross Ref]
8. Twyffels L, Gueydan C, Kruys V. Shuttling SR proteins: more than splicing factors. FEBS J. 2011;278:3246–3255. doi: 10.1111/j.1742-4658.2011.08274.x. [PubMed] [Cross Ref]
9. Teplova M, Patel DJ. Structural insights into RNA recognition by the alternative-splicing regulator muscleblind-like MBNL1. Nat Struct Mol Biol. 2008;15:1343–1351. doi: 10.1038/nsmb.1519. [PMC free article] [PubMed] [Cross Ref]
10. Cho DH, Tapscott SJ. Myotonic dystrophy: emerging mechanisms for DM1 and DM2. Biochim Biophys Acta. 2007;1772:195–204. doi: 10.1016/j.bbadis.2006.05.013. [PubMed] [Cross Ref]
11. Fardaei M, et al. Three proteins, MBNL, MBLL and MBXL, co-localize in vivo with nuclear foci of expanded-repeat transcripts in DM1 and DM2 cells. Hum Mol Genet. 2002;11:805–814. doi: 10.1093/hmg/11.7.805. [PubMed] [Cross Ref]
12. Kino Y, et al. Muscleblind protein, MBNL1/EXP, binds specifically to CHHG repeats. Hum Mol Genet. 2004;13:495–507. doi: 10.1093/hmg/ddh056. [PubMed] [Cross Ref]
13. Du J, et al. RNA toxicity and missplicing in the common eye disease fuchs endothelial corneal dystrophy. J Biol Chem. 2015;290:5979–5990. doi: 10.1074/jbc.M114.621607. [PMC free article] [PubMed] [Cross Ref]
14. Sznajder LJ, et al. Mechanistic determinants of MBNL activity. Nucleic Acids Res. 2016;44:10326–10342. [PMC free article] [PubMed]
15. Wollerton MC, Gooding C, Wagner EJ, Garcia-Blanco MA, Smith CW. Autoregulation of polypyrimidine tract binding protein by alternative splicing leading to nonsense-mediated decay. Mol Cell. 2004;13:91–100. doi: 10.1016/S1097-2765(03)00502-1. [PubMed] [Cross Ref]
16. Warf MB, Berglund JA. MBNL binds similar RNA structures in the CUG repeats of myotonic dystrophy and its pre-mRNA substrate cardiac troponin T. RNA. 2007;13:2238–2251. doi: 10.1261/rna.610607. [PubMed] [Cross Ref]
17. Goers ES, Purcell J, Voelker RB, Gates DP, Berglund JA. MBNL1 binds GC motifs embedded in pyrimidines to regulate alternative splicing. Nucleic Acids Res. 2010;38:2467–2484. doi: 10.1093/nar/gkp1209. [PMC free article] [PubMed] [Cross Ref]
18. Lambert N, et al. RNA Bind-n-Seq: quantitative assessment of the sequence and structural binding specificity of RNA binding proteins. Mol Cell. 2014;54:887–900. doi: 10.1016/j.molcel.2014.04.016. [PMC free article] [PubMed] [Cross Ref]
19. Du H, et al. Aberrant alternative splicing and extracellular matrix gene expression in mouse models of myotonic dystrophy. Nat Struct Mol Biol. 2010;17:187–193. doi: 10.1038/nsmb.1720. [PMC free article] [PubMed] [Cross Ref]
20. Zhang C, et al. Defining the regulatory network of the tissue-specific splicing factors Fox-1 and Fox-2. Genes Dev. 2008;22:2550–2563. doi: 10.1101/gad.1703108. [PubMed] [Cross Ref]
21. Masuda A, et al. CUGBP1 and MBNL1 preferentially bind to 3′ UTRs and facilitate mRNA decay. Sci Rep. 2012;2:209. doi: 10.1038/srep00209. [PMC free article] [PubMed] [Cross Ref]
22. Konieczny P, Stepniak-Konieczna E, Sobczak K. MBNL proteins and their target RNAs, interaction and splicing regulation. Nucleic Acids Res. 2014;42:10873–10887. doi: 10.1093/nar/gku767. [PMC free article] [PubMed] [Cross Ref]
23. Ho TH, et al. Muscleblind proteins regulate alternative splicing. EMBO J. 2004;23:3103–3112. doi: 10.1038/sj.emboj.7600300. [PubMed] [Cross Ref]
24. Hino S, et al. Molecular mechanisms responsible for aberrant splicing of SERCA1 in myotonic dystrophy type 1. Hum Mol Genet. 2007;16:2834–2843. doi: 10.1093/hmg/ddm239. [PubMed] [Cross Ref]
25. Kino Y, et al. MBNL and CELF proteins regulate alternative splicing of the skeletal muscle chloride channel CLCN1. Nucleic Acids Res. 2009;37:6477–6490. doi: 10.1093/nar/gkp681. [PMC free article] [PubMed] [Cross Ref]
26. Wang ET, et al. Transcriptome-wide regulation of pre-mRNA splicing and mRNA localization by muscleblind proteins. Cell. 2012;150:710–724. doi: 10.1016/j.cell.2012.06.041. [PMC free article] [PubMed] [Cross Ref]
27. Ule J, Jensen K, Mele A, Darnell RB. CLIP: a method for identifying protein-RNA interaction sites in living cells. Methods. 2005;37:376–386. doi: 10.1016/j.ymeth.2005.07.018. [PubMed] [Cross Ref]
28. Konig J, et al. iCLIP reveals the function of hnRNP particles in splicing at individual nucleotide resolution. Nat Struct Mol Biol. 2010;17:909–915. doi: 10.1038/nsmb.1838. [PMC free article] [PubMed] [Cross Ref]
29. Hafner, M. et al. PAR-CliP–a method to identify transcriptome-wide the binding sites of RNA binding proteins. J Vis Exp, 10.3791/2034 (2010). [PubMed]
30. Ule J, et al. CLIP identifies Nova-regulated RNA networks in the brain. Science. 2003;302:1212–1215. doi: 10.1126/science.1090095. [PubMed] [Cross Ref]
31. Jensen KB, Darnell RB. CLIP: crosslinking and immunoprecipitation of in vivo RNA targets of RNA-binding proteins. Methods Mol Biol. 2008;488:85–98. doi: 10.1007/978-1-60327-475-3_6. [PMC free article] [PubMed] [Cross Ref]
32. Sobczak K, Krzyzosiak WJ. RNA structure analysis assisted by capillary electrophoresis. Nucleic Acids Res. 2002;30:e124. doi: 10.1093/nar/gnf123. [PMC free article] [PubMed] [Cross Ref]
33. Yuan Y, et al. Muscleblind-like 1 interacts with RNA hairpins in splicing target and pathogenic RNAs. Nucleic Acids Res. 2007;35:5474–5486. doi: 10.1093/nar/gkm601. [PMC free article] [PubMed] [Cross Ref]
34. Sierakowska H, Sambade MJ, Agrawal S, Kole R. Repair of thalassemic human beta-globin mRNA in mammalian cells by antisense oligonucleotides. Proc Natl Acad Sci USA. 1996;93:12840–12844. doi: 10.1073/pnas.93.23.12840. [PubMed] [Cross Ref]
35. Friedman KJ, et al. Correction of aberrant splicing of the cystic fibrosis transmembrane conductance regulator (CFTR) gene by antisense oligonucleotides. J Biol Chem. 1999;274:36193–36199. doi: 10.1074/jbc.274.51.36193. [PubMed] [Cross Ref]
36. Dunckley MG, Manoharan M, Villiet P, Eperon IC, Dickson G. Modification of splicing in the dystrophin gene in cultured Mdx muscle cells by antisense oligoribonucleotides. Hum Mol Genet. 1998;7:1083–1090. doi: 10.1093/hmg/7.7.1083. [PubMed] [Cross Ref]
37. Bonifert T, et al. Antisense Oligonucleotide Mediated Splice Correction of a Deep Intronic Mutation in OPA1. Mol Ther Nucleic Acids. 2016;5:e390. doi: 10.1038/mtna.2016.93. [PMC free article] [PubMed] [Cross Ref]
38. Konieczny, P., Stepniak-Konieczna, E., Taylor, K., Sznajder, L. J. & Sobczak, K. Autoregulation of MBNL1 function by exon 1 exclusion from MBNL1 transcript. Nucleic Acids Res, 10.1093/nar/gkw1158 (2016). [PMC free article] [PubMed]
39. Wagner SD, et al. Dose-Dependent Regulation of Alternative Splicing by MBNL Proteins Reveals Biomarkers for Myotonic Dystrophy. PLoS Genet. 2016;12:e1006316. doi: 10.1371/journal.pgen.1006316. [PMC free article] [PubMed] [Cross Ref]
40. Echeverria GV, Cooper TA. Muscleblind-like 1 activates insulin receptor exon 11 inclusion by enhancing U2AF65 binding and splicing of the upstream intron. Nucleic Acids Res. 2014;42:1893–1903. doi: 10.1093/nar/gkt1020. [PMC free article] [PubMed] [Cross Ref]
41. Warf MB, Diegel JV, von Hippel PH, Berglund JA. The protein factors MBNL1 and U2AF65 bind alternative RNA structures to regulate splicing. Proc Natl Acad Sci USA. 2009;106:9203–9208. doi: 10.1073/pnas.0900342106. [PubMed] [Cross Ref]
42. Wang ET, et al. Antagonistic regulation of mRNA expression and splicing by CELF and MBNL proteins. Genome Res. 2015;25:858–871. doi: 10.1101/gr.184390.114. [PubMed] [Cross Ref]
43. Klinck R, et al. RBFOX1 cooperates with MBNL1 to control splicing in muscle, including events altered in myotonic dystrophy type 1. PLoS One. 2014;9:e107324. doi: 10.1371/journal.pone.0107324. [PMC free article] [PubMed] [Cross Ref]
44. Aartsma-Rus A, van Ommen GJ. Antisense-mediated exon skipping: a versatile tool with therapeutic and research applications. RNA. 2007;13:1609–1624. doi: 10.1261/rna.653607. [PubMed] [Cross Ref]
45. van Deutekom JC, et al. Antisense-induced exon skipping restores dystrophin expression in DMD patient derived muscle cells. Hum Mol Genet. 2001;10:1547–1554. doi: 10.1093/hmg/10.15.1547. [PubMed] [Cross Ref]
46. Dominski Z, Kole R. Selection of splice sites in pre-mRNAs with short internal exons. Mol Cell Biol. 1991;11:6075–6083. doi: 10.1128/MCB.11.12.6075. [PMC free article] [PubMed] [Cross Ref]
47. Kosaki A, Nelson J, Webster NJ. Identification of intron and exon sequences involved in alternative splicing of insulin receptor pre-mRNA. J Biol Chem. 1998;273:10331–10337. doi: 10.1074/jbc.273.17.10331. [PubMed] [Cross Ref]
48. Cartegni L, Wang J, Zhu Z, Zhang MQ, Krainer AR. ESEfinder: A web resource to identify exonic splicing enhancers. Nucleic Acids Res. 2003;31:3568–3571. doi: 10.1093/nar/gkg616. [PMC free article] [PubMed] [Cross Ref]
49. Paz I, Akerman M, Dror I, Kosti I, Mandel-Gutfreund Y. SFmap: a web server for motif analysis and prediction of splicing factor binding sites. Nucleic Acids Res. 2010;38:W281–285. doi: 10.1093/nar/gkq444. [PMC free article] [PubMed] [Cross Ref]
50. Dirksen WP, Li X, Mayeda A, Krainer AR, Rottman FM. Mapping the SF2/ASF binding sites in the bovine growth hormone exonic splicing enhancer. J Biol Chem. 2000;275:29170–29177. doi: 10.1074/jbc.M001126200. [PubMed] [Cross Ref]
51. Anczukow O, et al. SRSF1-Regulated Alternative Splicing in Breast Cancer. Mol Cell. 2015;60:105–117. doi: 10.1016/j.molcel.2015.09.005. [PMC free article] [PubMed] [Cross Ref]
52. Sen S, et al. Muscleblind-like 1 (Mbnl1) promotes insulin receptor exon 11 inclusion via binding to a downstream evolutionarily conserved intronic enhancer. J Biol Chem. 2010;285:25426–25437. doi: 10.1074/jbc.M109.095224. [PMC free article] [PubMed] [Cross Ref]
53. Sen S, Talukdar I, Webster NJ. SRp20 and CUG-BP1 modulate insulin receptor exon 11 alternative splicing. Molecular and cellular biology. 2009;29:871–880. doi: 10.1128/MCB.01709-08. [PMC free article] [PubMed] [Cross Ref]
54. Brook JD, et al. Molecular basis of myotonic dystrophy: expansion of a trinucleotide (CTG) repeat at the 3′ end of a transcript encoding a protein kinase family member. Cell. 1992;69:385. [PubMed]
55. Miller JW, et al. Recruitment of human muscleblind proteins to (CUG)(n) expansions associated with myotonic dystrophy. EMBO J. 2000;19:4439–4448. doi: 10.1093/emboj/19.17.4439. [PubMed] [Cross Ref]
56. Fu YH, et al. An unstable triplet repeat in a gene related to myotonic muscular dystrophy. Science. 1992;255:1256–1258. doi: 10.1126/science.1546326. [PubMed] [Cross Ref]
57. Chen KY, et al. Length-dependent toxicity of untranslated CUG repeats on Caenorhabditis elegans. Biochem Biophys Res Commun. 2007;352:774–779. doi: 10.1016/j.bbrc.2006.11.102. [PubMed] [Cross Ref]
58. Mootha VV, et al. TCF4 Triplet Repeat Expansion and Nuclear RNA Foci in Fuchs’ Endothelial Corneal Dystrophy. Invest Ophthalmol Vis Sci. 2015;56:2003–2011. doi: 10.1167/iovs.14-16222. [PMC free article] [PubMed] [Cross Ref]
59. Wheeler TM, et al. Reversal of RNA dominance by displacement of protein sequestered on triplet repeat RNA. Science. 2009;325:336–339. doi: 10.1126/science.1173110. [PMC free article] [PubMed] [Cross Ref]
60. Sobczak K, Wheeler TM, Wang W, Thornton CA. RNA interference targeting CUG repeats in a mouse model of myotonic dystrophy. Mol Ther. 2013;21:380–387. doi: 10.1038/mt.2012.222. [PubMed] [Cross Ref]
61. Rzuczek SG, et al. Precise small-molecule recognition of a toxic CUG RNA repeat expansion. Nat Chem Biol. 2017;13:188–193. doi: 10.1038/nchembio.2251. [PubMed] [Cross Ref]
62. Thornton CA, Wang E, Carrell EM. Myotonic dystrophy: approach to therapy. Curr Opin Genet Dev. 2017;44:135–140. doi: 10.1016/j.gde.2017.03.007. [PubMed] [Cross Ref]
63. Wojtkowiak-Szlachcic A, et al. Short antisense-locked nucleic acids (all-LNAs) correct alternative splicing abnormalities in myotonic dystrophy. Nucleic Acids Res. 2015;43:3318–3331. doi: 10.1093/nar/gkv163. [PMC free article] [PubMed] [Cross Ref]
64. Nakamori M, Taylor K, Mochizuki H, Sobczak K, Takahashi MP. Oral administration of erythromycin decreases RNA toxicity in myotonic dystrophy. Ann Clin Transl Neurol. 2016;3:42–54. doi: 10.1002/acn3.271. [PMC free article] [PubMed] [Cross Ref]
65. Oana K, et al. Manumycin A corrects aberrant splicing of Clcn1 in myotonic dystrophy type 1 (DM1) mice. Sci Rep. 2013;3:2142. doi: 10.1038/srep02142. [PMC free article] [PubMed] [Cross Ref]
66. Phair RD, Misteli T. High mobility of proteins in the mammalian cell nucleus. Nature. 2000;404:604–609. doi: 10.1038/35007077. [PubMed] [Cross Ref]
67. Childs-Disney JL, et al. Induction and reversal of myotonic dystrophy type 1 pre-mRNA splicing defects by small molecules. Nat Commun. 2013;4:2044. doi: 10.1038/ncomms3044. [PMC free article] [PubMed] [Cross Ref]
68. Dansithong W, Paul S, Comai L, Reddy S. MBNL1 is the primary determinant of focus formation and aberrant insulin receptor splicing in DM1. J Biol Chem. 2005;280:5773–5780. doi: 10.1074/jbc.M410781200. [PubMed] [Cross Ref]
69. Wojciechowska M, Taylor K, Sobczak K, Napierala M, Krzyzosiak WJ. Small molecule kinase inhibitors alleviate different molecular features of myotonic dystrophy type 1. RNA Biol. 2014;11:742–754. doi: 10.4161/rna.28799. [PMC free article] [PubMed] [Cross Ref]
70. Caceres JF, Krainer AR. Functional analysis of pre-mRNA splicing factor SF2/ASF structural domains. EMBO J. 1993;12:4715–4726. [PubMed]

Articles from Scientific Reports are provided here courtesy of Nature Publishing Group